For example, in a randomized clinical trial, Stone et al [5] showed no benefit of tocilizumab versus placebo on mechanical ventilation or death on day 28 in a population at inflammatory stage (median C-reactive protein level at 110.0 mg/L) of moderate to severe pneumonia (>95% of patients had a level of O2 <6l/minute delivered by nasal cannula or no O2 administration). This evidence concerns the gene CRP and pneumonia.